C1q autoantibodies in HIV infection correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins

C1q autoantibodies in HIV infection : correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins

Copyright 1999 Academic Press.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 90(1999), 2 vom: 19. Feb., Seite 247-55
Auteur principal: Prohászka, Z (Auteur)
Autres auteurs: Daha, M R, Süsal, C, Daniel, V, Szlávik, J, Bánhegyi, D, Nagy, K, Várkonyi, V, Horváth, A, Ujhelyi, E, Tóth, F D, Uray, K, Hudecz, F, Füst, G
Format: Article
Langue:English
Publié: 1999
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't Antigens, Bacterial Autoantibodies Autoantigens Bacterial Proteins Chaperonin 60 heat-shock protein 65, Mycobacterium Complement C1q 80295-33-6 plus... Chaperonins EC 3.6.1.-
LEADER 01000caa a22002652c 4500
001 NLM100141161
003 DE-627
005 20250201035258.0
007 tu
008 231222s1999 xx ||||| 00| ||eng c
028 5 2 |a pubmed25n0334.xml 
035 |a (DE-627)NLM100141161 
035 |a (NLM)10080837 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Prohászka, Z  |e verfasserin  |4 aut 
245 1 0 |a C1q autoantibodies in HIV infection  |b correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins 
264 1 |c 1999 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 29.03.1999 
500 |a Date Revised 19.11.2009 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Copyright 1999 Academic Press. 
520 |a Antibodies to solid phase C1q (C1qAb) were determined in 295 serum samples from 132 HIV-infected subjects and in sera from 140 HIV-seronegative healthy individuals as control. An ELISA method applied for the determination of C1qAb in other diseases was used. In part of these sera, other autoantibodies (antibodies reacting with 60-kDa human heat shock protein (hsp60) or mycobacterial hsp65; IgA and IgG class antibodies against the Fab and F(ab')2 moieties of IgG) as well as complement-mediated antibody-dependent enhancement/neutralization (C'-ADE) were also determined. Increased amount of C1qAb was found in HIV-infected subjects as compared with HIV-seronegative controls (P = 0.0138). In 17 of 132 (13.0%) seropositive individuals but only in 7/140 (5.0%) samples from the controls, the amount of C1qAb exceeded the upper limit (95th percentile) of the normal values (P = 0.031). The amount of C1qAb significantly decreased during a follow-up period of 65 months. C1qAb levels were found to strongly correlate to hsp60/65 autoantibodies but did not correlate or only weakly correlated to the amount of anti-Fab or anti-F(ab')2 autoantibodies measured in the same serum samples. Anti-C1q antibodies recognized the solid phase hsp60/65. Three predicted epitope regions of M. paratuberculosis hsp65 were able to bind efficiently C1q antibodies. An inverse correlation was found between C1qAb and C'-ADE, neutralization was more frequent in the sera with detectable C1qAb, whereas sera without C1qAb more likely enhanced HIV infection in vitro 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Antigens, Bacterial  |2 NLM 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a Autoantigens  |2 NLM 
650 7 |a Bacterial Proteins  |2 NLM 
650 7 |a Chaperonin 60  |2 NLM 
650 7 |a heat-shock protein 65, Mycobacterium  |2 NLM 
650 7 |a Complement C1q  |2 NLM 
650 7 |a 80295-33-6  |2 NLM 
650 7 |a Chaperonins  |2 NLM 
650 7 |a EC 3.6.1.-  |2 NLM 
700 1 |a Daha, M R  |e verfasserin  |4 aut 
700 1 |a Süsal, C  |e verfasserin  |4 aut 
700 1 |a Daniel, V  |e verfasserin  |4 aut 
700 1 |a Szlávik, J  |e verfasserin  |4 aut 
700 1 |a Bánhegyi, D  |e verfasserin  |4 aut 
700 1 |a Nagy, K  |e verfasserin  |4 aut 
700 1 |a Várkonyi, V  |e verfasserin  |4 aut 
700 1 |a Horváth, A  |e verfasserin  |4 aut 
700 1 |a Ujhelyi, E  |e verfasserin  |4 aut 
700 1 |a Tóth, F D  |e verfasserin  |4 aut 
700 1 |a Uray, K  |e verfasserin  |4 aut 
700 1 |a Hudecz, F  |e verfasserin  |4 aut 
700 1 |a Füst, G  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 90(1999), 2 vom: 19. Feb., Seite 247-55  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:90  |g year:1999  |g number:2  |g day:19  |g month:02  |g pages:247-55 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 90  |j 1999  |e 2  |b 19  |c 02  |h 247-55